Oramed to Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Kidron's presentation will take place on September 15 at 1:30 PM Eastern. Oramed specializes in oral drug delivery solutions, aiming to transform diabetes treatment with its lead candidate, ORMD-0801, the first oral insulin capsule. The company has completed multiple Phase II clinical trials and is also developing an oral GLP-1 analog capsule, ORMD-0901.

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020.

 

 

Presentation Details:
Presenter:  Nadav Kidron, CEO
Date: Tuesday, September 15, 2020
Time: 1:30 PM Eastern  
Online

About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential benefits of ORMD-0801 or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Logo: https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg

Company Contact
Estee Yaari
+1-844-9-ORAMED
estee@oramed.com

 

View original content:http://www.prnewswire.com/news-releases/oramed-to-present-at-hc-wainwright-global-investment-conference-301123771.html

SOURCE Oramed Pharmaceuticals Inc.

FAQ

When will Oramed Pharmaceuticals present at the H.C. Wainwright 22nd Annual Global Investment Conference?

Oramed Pharmaceuticals will present at the conference from September 14-16, 2020, with CEO Nadav Kidron's presentation on September 15 at 1:30 PM Eastern.

What is the focus of Oramed Pharmaceuticals regarding diabetes treatment?

Oramed Pharmaceuticals focuses on developing oral drug delivery systems, particularly its lead candidate ORMD-0801, which aims to be the first oral insulin capsule for diabetes treatment.

What technology does Oramed Pharmaceuticals utilize for oral drug delivery?

Oramed Pharmaceuticals has developed a novel Protein Oral Delivery (POD™) technology for its oral drug delivery solutions.

What other products is Oramed Pharmaceuticals developing?

In addition to ORMD-0801, Oramed is also developing an oral GLP-1 analog capsule called ORMD-0901.

Where can I find more information about Oramed Pharmaceuticals?

More information about Oramed Pharmaceuticals can be found on their official website at www.oramed.com.